尿LIF水平与IgA肾病疾病预后及甲泼尼龙治疗反应的相关性
在506例活检确诊IgA肾病的回顾性队列中,基线尿LIF/尿肌酐升高与肾脏进展风险独立相关(每自然对数增量HR 2.16)。TESTING试验亚组显示甲泼尼龙组uLIF/Cr降幅显著大于安慰剂组,且LIF下降组肾脏进展风险显著更低(校正HR 0.431)。
要点
- 基线uLIF/Cr升高与IgA肾病患者肾脏进展风险增加独立相关(HR 2.16)。
- 甲泼尼龙组uLIF/Cr降幅在6个月和12个月均显著大于安慰剂组。
- LIF下降组较未下降组肾脏进展风险显著更低(校正HR 0.431)。
核心结论
- uLIF/Cr水平与IgA肾病肾脏预后相关,其下降可能提示接受甲泼尼龙治疗的患者结局改善,可能作为预测肾脏预后和治疗反应的生物标志物。
研究设计与样本
- 回顾性队列研究纳入506例活检确诊的IgA肾病患者,采用酶联免疫吸附法测定基线uLIF浓度。
- 另从TESTING试验中衍生一个亚组,用于探讨uLIF变化与甲泼尼龙治疗反应的关系。
主要发现
- 中位随访35个月期间,预后队列中16.6%的参与者达到复合肾脏进展事件。
- TESTING亚组中,甲泼尼龙组uLIF/Cr降幅显著大于安慰剂组(6个月:41.9% vs 25.4%,P=0.039;12个月:59.2% vs 19.8%,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Leukemia inhibitory factor (LIF) has been implicated in the production of galactose-deficient immunoglobulin A1 (IgA1) and development of renal fibrosis, and has emerged in several genome-wide association studies as a hotspot gene of IgA nephropathy (IgAN). Therefore, we hypothesize that urinary LIF (uLIF) could predict the renal prognosis and/or treatment response to immunosuppressive therapy in IgAN patients. METHODS: A prognostic study was conducted in a retrospective cohort of 506 biopsy-confirmed IgAN patients. Baseline uLIF concentrations were measured using enzyme-linked immunosorbent assay. Kidney disease progression was defined as a 40% decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease or death due to kidney disease. Additionally, a subcohort derived from the Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) trial was used to investigate the association between changes in uLIF and the response to methylprednisolone therapy in IgAN patients. RESULTS: Over a median of 35 months of follow-up, 16.6% participants of the prognostic cohort reached the composite kidney progression event. After adjusting for sex, age, eGFR, proteinuria and systolic blood pressure, elevated levels of uLIF/urinary creatinine (uLIF/Cr) were independently associated with an increased risk of kidney progression [per natural log (uLIF/Cr) increment: hazard ratio (HR) 2.16; 1.13-4.13; P for trend 0.019]. In TESTING subcohort, the methylprednisolone group showed a significant greater reduction in uLIF/Cr than the placebo group (41.9% vs 25.4% at 6th month, P = .039; 59.2% vs 19.8% at 12th month, P < .001). The LIF decline group exhibited a significant lower risk of kidney progression compared with LIF non-decline group (adjusted HR 0.431; 0.255-0.730; P for trend 0.002). CONCLUSION: This study provides strong initial evidence that uLIF/Cr levels are linked to renal prognosis in IgAN. Moreover, reductions in uLIF/Cr may indicate improved outcomes in patients receiving methylprednisolone. Collectively, our findings suggest uLIF/Cr levels may serve as a valuable biomarker for predicting both renal prognosis and treatment response in IgAN patients.
引用
- Zhang L, Dong Y, Xie L, et al. Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy. Nephrol Dial Transplant. 2025. PMID: 40848236. doi:10.1093/ndt/gfaf164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。